Proteome Sciences has announced the signing of two additional substantial Good Clinical Laboratory Practice (GCLP) contracts, building on momentum from its recent contract announcement on 8 December 2025.
The two new agreements, valued at more than $1.5 million, mark another significant win for the clinical laboratory services provider.
Proteome Sciences shares were 25% higher at the time of writing.
The trial samples are expected to be shipped in late Q1 of this year, with the majority of work under both contracts scheduled for completion during 2026.
“We continue to experience strong interest in GCLP work from major biopharma clients in both the US and Europe and expect further orders to materialise in due course,” said Richard Dennis, Chief Commercial Officer of Proteome Sciences.
“These new contracts together with contracts previously secured provide a strong order book supporting our business through 2026.”
Proteome Sciences announced a third contract from a US biopharmaceutical company in December after announcing a $1m deal in February last year.